Market Overview

Sagent Pharma Announces Termporary Importation of Sodium Bicarbonate Injection

Related SGNT
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
ETFs For The Next Pharma Takeover Candidates

Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced that due to the current critical shortage of Sodium Bicarbonate Injection, USP in the United States market, Sagent, in cooperation with the U.S. Food and Drug Administration ("FDA"), has initiated the temporary importation into the U.S. of a non-FDA approved 8.4% Sodium Bicarbonate Injection (1 mEQ/mL) from Phebra Pty Ltd., an Australian manufacturer. Please refer to the Dear Healthcare Provider Letter, posted on the FDA website, for further information about availability of supply.

Posted-In: News


Related Articles (SGNT)

Get Benzinga's Newsletters